Barclays Raises Johnson & Johnson (JNJ) Price Target on Strong Pharma Momentum

On April 15, Barclays expert Matt Miksic raised the firm’s terms proposal connected Johnson & Johnson (NYSE:JNJ) to $255 from $234. It reiterated an Equal Weight standing connected the shares. The expert noted that the company’s pharma portion delivered its sixth consecutive 4th of double-digit integrated growth. In a probe note, Barclays said it expects J&J’s caller products, on with “durable” halfway maturation successful aesculapian exertion and pharma, to enactment its extremity of double-digit income maturation by the extremity of the decade.

During the Q1 2026 net call, CEO and Chairman Joaquin Duato said the institution delivered operational income maturation of 6.4%. He explained that the company’s maturation strategy remains focused connected oncology, immunology, neuroscience, cardiovascular, surgery, and vision. He besides said the institution present has 28 platforms oregon products generating astatine slightest $1 cardinal successful yearly gross and is connected way to scope its 2026 people of $100 cardinal successful yearly gross for the archetypal time.

Speaking astir oncology, Duato said DARZALEX continues to service arsenic the golden modular successful aggregate myeloma, with income of $4 cardinal and operational income maturation of 18%. He besides pointed to the FDA support of TECVAYLI successful operation with DARZALEX FASPRO, noting that the regimen could presumption itself arsenic a imaginable caller modular of attraction arsenic aboriginal arsenic the second-line setting.

Johnson & Johnson (NYSE:JNJ) and its subsidiaries are engaged successful the probe and development, manufacture, and merchantability of a scope of products successful the healthcare field. The institution operates done 2 segments: Innovative Medicine and MedTech.

While we admit the imaginable of JNJ arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 14 Value Stocks with Highest Dividends and Early Retirement Portfolio: Top 15 Stocks to Buy

Disclosure: None. Follow Insider Monkey connected Google News.